Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutathera safety and dosimetry study in adolescents with SSTR-positive neuroendocrine tumors
2020-002951-39Phase 2Terminated
- Sponsor
- Advanced Accelerator Applications
- Start
- Nov 2020
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate in Gastroenteropancreatic Carcinoid Tumor, pheochromocytoma and Paraganglioma (PGL), sponsored by Advanced Accelerator Applications. Primary endpoint: Target organ absorbed radiation doses. Started Nov 2020; status: terminated.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Gastroenteropancreatic Carcinoid TumorpheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on 2020-002951-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002951-39.